Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 2 | 2017 | 32 | 0.260 |
Why?
|
| Lymphoma | 2 | 2019 | 327 | 0.230 |
Why?
|
| MicroRNAs | 3 | 2017 | 893 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 178 | 0.190 |
Why?
|
| Germinal Center | 3 | 2017 | 37 | 0.180 |
Why?
|
| Lymph Nodes | 3 | 2017 | 375 | 0.170 |
Why?
|
| Hyalin | 2 | 2017 | 6 | 0.170 |
Why?
|
| Castleman Disease | 2 | 2017 | 15 | 0.170 |
Why?
|
| Orbital Neoplasms | 2 | 2019 | 49 | 0.170 |
Why?
|
| RNA, Viral | 3 | 2017 | 513 | 0.160 |
Why?
|
| Antigens, CD20 | 2 | 2017 | 43 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 61 | 0.140 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 34 | 0.140 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2017 | 1 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1315 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 305 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2013 | 526 | 0.130 |
Why?
|
| Genes, myc | 2 | 2012 | 95 | 0.110 |
Why?
|
| Viral Load | 1 | 2017 | 405 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 2 | 2015 | 645 | 0.110 |
Why?
|
| Marek Disease | 1 | 2014 | 2 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2017 | 284 | 0.110 |
Why?
|
| Breast Implants | 1 | 2013 | 30 | 0.100 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1616 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 50 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1614 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2015 | 339 | 0.100 |
Why?
|
| Genes, bcl-2 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 121 | 0.100 |
Why?
|
| Blast Crisis | 1 | 2011 | 17 | 0.090 |
Why?
|
| Mastocytosis, Systemic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 313 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 275 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 148 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 109 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 104 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 311 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 2011 | 135 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 671 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 163 | 0.070 |
Why?
|
| Middle Aged | 11 | 2019 | 28730 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2017 | 755 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2011 | 437 | 0.070 |
Why?
|
| Aged | 9 | 2019 | 21134 | 0.070 |
Why?
|
| Immunophenotyping | 3 | 2017 | 337 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 606 | 0.060 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2004 | 2 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6862 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 451 | 0.050 |
Why?
|
| Biopsy | 2 | 2019 | 1248 | 0.050 |
Why?
|
| Adult | 8 | 2019 | 31533 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 62 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2014 | 12858 | 0.050 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2002 | 7 | 0.050 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2002 | 7 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2002 | 26 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 910 | 0.050 |
Why?
|
| Male | 10 | 2019 | 64819 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 2679 | 0.040 |
Why?
|
| Humans | 15 | 2019 | 130912 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1802 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2636 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1068 | 0.040 |
Why?
|
| Gene Rearrangement | 2 | 2012 | 323 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 341 | 0.040 |
Why?
|
| Female | 9 | 2019 | 70740 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5256 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 118 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 47 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1904 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 247 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1767 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 5095 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2011 | 314 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2015 | 36 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 790 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 768 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2015 | 58 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 530 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 108 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 896 | 0.030 |
Why?
|
| Brachial Plexus | 1 | 2014 | 18 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 809 | 0.030 |
Why?
|
| Birds | 1 | 2014 | 86 | 0.030 |
Why?
|
| Lewis X Antigen | 1 | 2013 | 11 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 18 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2013 | 25 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 989 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 123 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 83 | 0.030 |
Why?
|
| Reed-Sternberg Cells | 1 | 2013 | 19 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 147 | 0.030 |
Why?
|
| Plasma Exchange | 1 | 2014 | 83 | 0.030 |
Why?
|
| Time Factors | 2 | 2013 | 6275 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 4930 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2013 | 73 | 0.020 |
Why?
|
| Microvessels | 1 | 2013 | 66 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 306 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 215 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 294 | 0.020 |
Why?
|
| Karyotyping | 1 | 2012 | 314 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 222 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2287 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 272 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 232 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 63 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 53 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 74 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 1166 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 738 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1235 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 418 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2950 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1395 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1500 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 693 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2191 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2004 | 10 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2004 | 208 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 10037 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1821 | 0.010 |
Why?
|
| United States | 1 | 2019 | 11716 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3833 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1490 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 17483 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 549 | 0.010 |
Why?
|
| Chromatin | 1 | 2002 | 491 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 34275 | 0.010 |
Why?
|